Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anand Bidarkar appointed vice-president of BD for Ecron Acunova

This article was originally published in Scrip

Executive Summary

Dr Anand Bidarkar has been hired as vice-president of business development for the Ecron Acunova group. He has extensive functional experience in operations, business development, strategic partnerships and leading business units with multibillion dollar groups like Novartis, inVentiv and Apollo as well as with mid-sized firms like Sun Pharmaceuticals. Prior to joining EA, Dr Bidarkar was working with SIRO Clinpharm as vice-president of business development. He spearheaded alliance formation with complimentary service providers and transformed the business model of the company from being dependent on single project, single country contracts to programme level and multinational deals.

You may also be interested in...



Hoops, hoopla, big ideas and diabetes

Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.

Scrip Asia 100 league tables 2013

How Dennis Gillings took a gamble and built a $3.7bn business

"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"

Related Companies

UsernamePublicRestriction

Register

SC016696

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel